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a b s t r a c t
The constantly increasing requests for the measurement of serum 25-hydroxyvitamin D over the last
years has led reagent manufacturers to market different automated and semi-automated methods, that
being unfortunately not fully harmonized, yield different results. Liquid chromatography coupled to
tandem mass spectrometry (LC/MS2) has more recently been introduced. This approach allows the
distinction between the two forms of 25-hydroxyvitamin D and to measure other metabolites. This
approach also requires harmonization to curtail the differences between the different analytical
methods. To meet this requirement, the American National Institutes of Health (NIH), the Centre for
Disease Control and Prevention (CDC) in Atlanta, the National Institute of Standards and Technology
(NIST) and the vitamin D Reference laboratory of Ghent University have pooled their expertise to
develop a standardization program.
This article reviews the main elements and the difﬁculties of the automated and semi-automated
methods for 25-hydroxyvitamin D, from sample preparation to the analytical phase, as well as those
related to mass spectrometry. It also emphasizes the need for standardization to better deﬁne the clinical
decision thresholds of vitamin D nutritional status.
& 2015 Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
The role of cholecalciferol or vitamin D3 in growth and bone metabolism is well established [1]. Its effects in the prevention and
treatment of diseases as varied as diabetes, multiple sclerosis and cancer have also been reported, but are still matter of debate [2–6]. Both
the Institute of Medicine (IoM) [7] and the Agency for Healthcare Research and Quality (AHRQ) [8] have published extensive documents
dampening the optimism aroused by these reports. The AHRQ report [8] makes the case that studies (observational, randomised
controlled interventions) and systematic reviews or meta-analyses based on those, involved different types of assays that, except for the
most recently published, did not use appropriate reference material. It also shows, as a series of bubble plots, that there was an important
variation in responses to vitamin D supplementation (Fig. 1). This apparent variation is multifactorial. The individual response to sun
exposure and the formulation of the vitamin D supplement are parts of the equation. However, inter-laboratory variations also contribute
to this observation as they hinder comparison between results. Indeed, the inter-laboratory differences between the mean serum 25-
hydroxyvitamin D (25OHD) values, that reached almost 32%, according to a Vitamin D External Quality Assessment Scheme (DEQAS)
survey in 1994, could have lead to misclassiﬁcation of patients in terms of vitamin D nutritional status. Since then, the standardization
process has improved, and in 2009, the inter-laboratory imprecision had dramatically decreased [9], and thus if similar experiments were
conducted today, the vitamin D dose-response relationship should be stricter. However at the present time, the observed wide-spread
difference in circulating 25OHD concentrations restrain the conclusions of past epidemiological studies on the circulating 25OHD
concentrations required for optimal health status, and confuse the efforts in developing international evidence-based public health
guidelines. To solve this challenge, the NIH Ofﬁce of Dietary Supplements (ODS), jointly with the Center for Disease Control (CDC) National
Center for Environmental Health (NCEH), the National Institute of Standards and Technology (NIST) and Ghent University, established in
2010 the Vitamin D Standardization Program (VDSP) with the main goal of promoting consistency in the methods for the measurement of
25OHD [10]. This consortium is thus advocating, based on the recommendations of Stöckl et al. [11], an imprecision (CV) of r10% and a
bias r5% as current goals for the analytical performance of vitamin D assays in routine clinical laboratories [12]. This initiative has
resolved the imprecision issue. However, the trueness or accuracy although improved, remains a work in progress.
As it has often been mentioned, the number requests for the measurement of circulating 25OHD, the accepted biomarker for the
vitamin D nutritional status [13,14], has constantly increased over the last 3 decades, imposing structural and ﬁnancial burdens on
laboratory facilities and public funding. The Ontario Health Technology Advisory Committee (OHTAC) has reported that, the volume of
laboratory vitamin D tests had increased from approximately 30,000 in 2004 to over 730,000 in 2009 [15]. Similar observations were
made worldwide. This increased request load has lead most of the clinical laboratories to abandon manual binding-protein assays and
radio-immunoassays (RIAs), the methods mostly utilized clinical laboratories in the 1980s and early 1990s, in favor of automated
competitive binding-protein assays (CBPA), enzyme-linked immunoassays (ELISAs) or chemiluminescent immunoassays (CLIA). Techni-
ques based on high-performance liquid chromatography (HPLC), coupled or not tandem mass spectrometry (LCMS-MS), while more exact,
Fig. 1. Relationship between doses of vitamin D3 supplementation and net changes in serum 25OHD concentrations in RCTs by assay type. Legends: Each empty circle
represents one study. The area of the circle is proportional to the inverse of the within-study variances. The larger the bubble is, the larger the sample size and the smaller
the standard error of the changes in 25OHD.
Reprinted with permission from Newberry et al. [8].
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are still the privilege of specialised and research laboratories. These physicochemical approaches are however indispensible when one
realizes that vitamin D is not a single entity. Indeed, there are 2 common forms, vitamin D3 (endogenously produced or dietary) and
vitamin D2 from plant origin or from supplements. Vitamin D2 differs from its D3 homolog by having a double bond at C22–C23 and by
being methylated at C24. These 2 structural modiﬁcations are reported, although not unanimously, to induce metabolic and functional
alterations. For example, Biancuzzo et al. [16] have shown that orange juice supplemented with vitamin D2 or vitamin D3 was as effective
in maintaining vitamin D status in adults, To the contrary Armas et al. [17] have shown that vitamin D2 was 1/3 less potent than vitamin D3
in maintaining serum total 25OHD concentrations after a single 50,000 IU oral dose, and that the difference was essentially due to a more
rapid clearance/metabolism of vitamin D2. In terms of biological function, Tsugawa et al. [18] have shown in a variety of in vitro and ex vivo
models, that binding afﬁnity for the vitamin D receptor (VDR), bone-resorbing activity and cell-differentiating effects of 1α,25(OH)2D2
were almost comparable to 1α,25(OH)2D3. The picture is furthermore complexiﬁed as the 2 vitamin D precursors exist as A-ring
diastereoisomers or epimers at carbon 3 (3α and 3β) that are hydroxylated to their metabolites, which respective physiological functions
remain a matter of debate. While in vitro, the downstream metabolite of C3-epi-25OHD3 (3-epi-25-OHD3, 3β25-OHD3), 3-epi-1,25(OH)2D3
(3β,1,25(OH)2D3) displays less potent gene-regulatory effects on some vitamin D receptor-responsive genes involved in bone metabolism
than 1α,25(OH)2D3; it is as potent with regard to the suppression of the transcription of the PTH gene [19,20]. These data support the need
for, further research and for distinguishing vitamin D metabolite epimers.
Despite the recent technological advances, the variety of circulating vitamin D metabolites, and the complex nature of the biological
matrix in which they bathe, make the measurement of 25OHD difﬁcult. Many important issues have still to be resolved to obtain an
accurate measure of serum 25OHD concentration. Each phase of the process will be reviewed in order to provide clinical laboratories with
information on the difﬁculties they have to overcome.
2. The sample preparation phase
In order to understand the problems related to the recovery of 25OHD during the extraction procedures, one must have some
knowledge of the physiological processes involved in its transport. Due to their lipophilicity, vitamins D3 and D2, as well as their respective
hydroxylated metabolites (ligands), must be transported by amphoteric carriers. Although vitamin D binding-protein (DBP) is their
predominant transporter, albumin and lipoproteins are also important components. Whereas vitamin D synthesized in the skin is
preferentially transported by DBP to be hydroxylated in the liver, lymphatic chylomicrons and lipoproteins mediate its transport and
hepatic uptake [21–24].
Each ligand–vitamin D carrier complex possesses its own afﬁnity constant. For example 25OHD binds DBP with high afﬁnity
(Ka¼5108 M), whereas 1α,25(OH)2D3, the hormonal form of vitamin D3, exhibits a lower afﬁnity (Ka¼4107 M) [25,26]. In both
cases the carrier being in large excess, o5% of the DBP sites are occupied, and the free concentrations of the metabolites are extremely
low. The other transporters have similar kinetics at however different orders of magnitude. It becomes apparent that the dissociation of
25OHD from the collection of the carriers must be highly efﬁcient in order to obtain an accurate total quantitation. The problem is not so
much for binding-protein assays, radio-immunoassays, high performance liquid chromatography, coupled or not to mass spectrometry,
that all require an organic extraction step destroying the binding capacity of the carriers, but for automated non-extracting assays for
which organic solvents are not compatible, and in which alternative releasing agents with proprietary protection are used. Indeed the
varying serum DBP concentration with physiological and pathological conditions, such as pregnancy, estrogen therapy or renal failure [27–
29], affects the dissociation of vitamin D metabolites from the carrier and the competition kinetics involved in methods relying on pH
changes or blocking agents. In support of this statement, several reports have highlighted the inaccuracy of total 25OHD measurement by
automated immunoassays and competitive binding-protein assays performed in populations with different levels of DBP [30–33].
Evaluation of the recovery of 25OHD3 and 25OHD2 added to serum or plasma samples is customary in evaluating the efﬁciency of the on-
line dissociation step from the binding components. The validity of such in vitro recovery experiments is founded on the proviso that
exogenous and endogenous vitamin D metabolites fully equilibrate with and bind equally to all serum binding components. In practice,
this may however not occur. The rise in serum pH during storage, decreasing the afﬁnity of binding proteins for vitamin D metabolites,
might stimulate the sequestration of exogenous 25OHD by serum components, such as lipids or lipoproteins. Carter et al. [34] and Horst
[35] have reported this artefact showing an under-recovery of exogenously added 25OHD in automated assays. This has been extended to
methods based on HPLC-tandem-mass spectrometry, when Lankes et al. [36] have shown that the recovery of 25OHD was affected by
suboptimal extraction conditions. These observations, that elude complete understanding, question the present process of recovery
experiments, and warrant caution in interpreting reported data.
3. The analytical phase
Dietary supplements currently provide 2 forms of vitamin D: vitamin D3 (cholecalciferol) and vitamin D2 (ergocalciferol). It is therefore
essential that the analytical methods be able to measure the 2 forms equally in order to avoid an underestimation of the circulating total
25OHD in vitamin D2 supplemented individuals [37–40]. On the other hand, they must be able to distinguish C3-epi-25OHD3 and 24,25
(OH)2D, present in different proportions and to avoid an overestimation of circulating 25OHD. This is particularly important for samples
from infants under the age of 1 year [41,42] in which C3-epi-25OHD3 constitutes the major proportion of the total 25OHD. A number of
assays have been published and marketed, certain of which claim to achieve these goals. The following paragraphs address their
characteristics.
4. Binding-protein assays and immunoassays
Table 1a summarizes some of the characteristics of the CBPAs and immunoassays. A limited number of CBPAs have been reported and
used clinically between 1971 and 1980. Haddad et al. [43] reported ﬁrst a manual CBPA for the measurement of serum 25OHD. The
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method was based on the displacement of 3H-labeled 25OHD3 from post-microsomal kidney supernatants of rachitic rats by 25OHD
extracted from human serum and puriﬁed by chromatography on silicic acid columns. The authors suggested that this assay recognized
equally 25OHD3 and 25OHD2. The assay analytical sensitivity was 10 nmol/L. Almost 10 years later, Delvin et al. [44] published a simpliﬁed
CBPA using a commercially available bovine α-globulin enriched fraction (Cohn fraction IV). The serum samples, spiked with puriﬁed 3H-
25OHD3, for recovery calculation purposes, were chromatographed on silicic acid columns after lipoprotein precipitation with heparin/
MnCl2. The analytical sensitivity was 5 nmol/L. Although both 25OHD3 and 25OHD2 were equally recognized, contrary to the rat kidney
extracts, the α-globulin fraction showed no afﬁnity for 24,25(OH)2D. These assays requiring chromatographic puriﬁcation on silicic acid
and Sephadex LH-20 column after organic extraction were time-consuming and could not be implemented in routine clinical laboratories.
In 1984, Bouillon et al. [45] described a non-chromatographic direct assay for 25OHD using rachitic rat serum as the source of DBP, after
extraction with ethylacetate and cyclohexane. It measured 25OHD3 and 25OHD2 equally and exhibited a 100% cross-reactivity for 24,25
(OH)2D. Parviainen et al. [46] published in 1981, a method based on HPLC separation of vitamin D metabolites and their subsequent
measurement with a CBPA for 25OHD and 24,25(OH)2D, and a vitamin D-receptor assay for 1α,25(OH)2D. Although the recovery of the
labeled metabolites was relatively low, the coefﬁcient of variation (CV) was o10% for 25OHD. This method proved to be time-consuming
and hence was not applied for routine purposes by other groups. Although the above assays exhibited clinically acceptable analytical
sensitivity and imprecision, the development of polyclonal antibodies directed against 25OHD that lead to RIAs, and the simpliﬁcation of
HPLC equipment made them obsolete and allowed the introduction of these novel technologies in clinical laboratories.
5. Radio-immunoassays
RIAs, developed early in the 1980s, constitute the next generation of assay methods. In 1984, Bouillon et al. [45] ﬁrst described a
simpliﬁed non-chromatographic RIA, based on the production of rabbit polyclonal antibodies directed against BSA-25OHD3-hemisuccinate
conjugate and the competition of the serum-extracted 25OHD for [26(27)-methyl-3H]-25OHD3 as tracer. Although the assay was
analytically as sensitive as the CBPA, the 2 anti-sera produced had widely different characteristics in terms of speciﬁcity: the cross-
reactivity varying between 0% and 11% for 25OHD2 and 40 to 270% for 1α,25(OH)2D3. The second, developed by Hummer et al. [47],
required a preliminary chromatography step. As neither assays measured 25OHD2 their utility was limited in assessing total vitamin D
nutritional status, at a time when vitamin D2 was widely used as dietary supplement. The next year, Hollis et al. [48] described and
validated a non-chromatographic radioimmunoassay based on an anti-serum raised against the 23,24,25,26,27-pentanor-C-(22)-
carboxylic acid vitamin D-BSA conjugate. [26,27-methyl-3H]-25OHD3 was also used as tracer. Although the antibody had little afﬁnity
for both 1α,25(OH)2D3 and 1α,25(OH)2D2 (75%) or for vitamin D3 or D2 (710%), it had a 100% cross-reactivity for 25OHD2 and other
known vitamin D metabolites. The radically different recovery of labeled 25OHD3 depending whether the tracer was added to the sample
before or after the addition of acetonitrile was of concern. In order to obtain a quantitative recovery, the tracer had to be added after the
addition of acetonitrile. When added to the native sample and equilibrated before the extraction step, the recovery dropped to 753%. One
may therefore question whether the endogenous 25OHD was quantitatively recovered. To further confuse matters, in the above-
mentioned assays, only 3H-25OHD3 was used to monitor recover. This was a limitation, as Stryd et al. [49] had emphasized as soon as 1978,
Table 1a
Characteristics for in-house manual competitive binding-protein and radioimmunological 25OHD assays.
In-house and commercial manual assays
Reference Extraction and puriﬁcation
procedures
Vehicle for
assay
solubilization
Assay principle Equivalence for 25OHD2/
25OHD3, Cross-reactivity
C3-epi/24,25(OH)2D
Traceability,
recovery
LOQ/(LOD)
(nmol/L)
Precision,
intra-assay,
inter-assay,
CV
Haddad et al. [43] Plasma, 1 ml diethyl ether, silicic
acid chromatography
Absolute
ethanol
Rachitic rat kidney
extracts CBPA, 3H-
25OHD as tracer
Equivalence: NR, cross-
reaction: NR
Traceability
NR, 25OHD3
64.1710.9%
NR/(10) 14% at
40 nmol/L,
NR
Delvin et al. [44] Serum 500 μl, lipoprotein
precipitation (NaHep/MnCl2) diethyl
ether, silicic acid chromatography
Absolute
ethanol
Bovine □-globulin
CBPA, 3H-25OHD as
tracer
Equivalence: 74%/100%,
No cross-reactivity for
24,25(OH)2D
Traceability
NR, 25OHD3
9071.6%
NR 8.9% at
54 nmol/l,
8.4% at
37 nmol/L
Bouillon et al.
[45]
Serum 100 μl, EtAc/cycloHexane
(1:1 v/v)
Absolute
ethanol
Rachitic rat serum
CBPA, 3H-25OHD as
tracer
Equivalence: Yes, 100%
cross-reactivity for 24,25
(OH)2D
Traceability
NR, 25OHD3
10778.9%
NR/(2.5) 5.6% at
45 nmol/L,
NR
Parviainen et al.
[46]
Serum 100–500 μl, EtOH 150 μl,
2-propanol/hexane, 2:1 vol/vol
hexane, silicic acid chromatography
Absolute
ethanol
Human serum
CBPA, 3H-25OHD as
tracer
Equivalence: Yes, 100%
cross-reactivity for 24,25
(OH)2D
Traceability
NR, 25OHD3
7777%
NR/NR NR 8%,
Conc. NR
Hummer et al.
[47]
Serum 500 μl MeCN SPE Absolute
ethanol
RIA, 3H-25OHD3 as
tracer
Equivalence: 2.2%/100%,
10% cross-reactivity for
24,25(OH)2D
Traceability
NR, 25OHD3
93.7–115.1%
NR/(4.3) 4.5% at
54 nmol/l,
10.4% at
32 nmol/L
Hollis et al. [48] Plasma 25 μl MeCN Absolute
ethanol
RIA, 3H-25OHD3 as
tracer
Equivalence: Yes, 100%
cross-reactivity for 24,25
(OH)2D
Traceability
NR, 25OHD3
108718%
NR/(7.5) o13% Conc.
NR
Hollis et al. [50] Plasma/serum 25 μl MeCN Absolute
ethanol
RIA, 125I-CC
derivative
Equivalence: Yes, 100%
cross-reactivity for 24,25
(OH)2D
Traceability
NR, 25OHD3
97710%
NR/(7.0) 5.6% at
23 nmol/L,
15.9% at
23 nmol/L
NR: Not reported.
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total 25OHD could be underestimated since the recovery of the 2 vitamin D isomers may not necessarily be identical in the extraction
processes.
Eight years later Hollis et al. [50] described a RIA based on goat anti 23,24,25,26,27-pentanor-C(22)-carboxylic acid of vitamin D-BSA
conjugate and 125I-vitamin D-23,24,25,26,27-pentanor-C(22)-carboxylic-amide-3-aminopropyl as the tracer. As in the former assay [48]
this antibody had little afﬁnity for 1α,25(OH)2D3 and 1β,25(OH)2D2 (72.5%) or for vitamin D3 or D2 (o1%), and had a 100% cross-reactivity
for 25OHD2 and other vitamin D metabolites. Despite the fact that collectively these metabolites account for a small percentage, the assays
probably over-quantiﬁed the “true” 25OHD concentration. Nevertheless this RIA gave a better estimate of the total vitamin D status as
both 25OHD3 and 25OHD2 could be measured equally, on the proviso that 25OHD was quantitatively recovered during the extraction
procedure. This assay probably led to the 1st commercial radioimmunoassay for the measurement of 25OHD marketed by DiaSorin
(Stillwater, MN, USA).
Table 1b summarizes the characteristics of the marketed RIAs and automated non-radioactive immunoassays. It can be appreciated that
the 2 RIAs listed differ in their performance claimed by the respective manufacturers. The DiaSorin assay measures 25OHD2 and 25OHD3
equally whereas the IDS RIA underestimates 25OHD2 by 25%. The different afﬁnity of the antibodies may be due to the difference in the
vitamin D analog used to raise the polyclonal antibodies. DiaSorin use a vitamin D analog that lacks the side-chain while retaining the
Table 1b
Characteristics for manual and automated commercial 25OHD assays according to insertrs.
Platform vendor Extraction and
puriﬁcation
procedures
Assay principle Equivalence
25OHD2/25OHD3,
Cross-reactivity
(C3-epi/24,25
(OH)2D
Traceability, recovery (%) LOQ/(LOD)
(nmol/L)
Precision, intra-assay,
inter-assay, CV (%)
DiaSorin S/P acetonitrile RIA, 125I-CC, derivative goat
polyclonal Ab
Equivalence: Yes,
cross-reactivity:
Yes NR/100%
Calibrators traceable to a pure
preparation of the 25OHD Ag
calculated by
spectrophotometry
6.25a/(4.0) 11.7% at 21.5 nmol/L,
9.4% at 21.5 nmol/L
Immuno Diagnostics
Ltd.
S/P 50 μl, NaOH,
acetonitrile
RIA, 125I-25OHD Equivalence: 75%/
100%, cross-
reactivity: NR/
Z100%
Calibrators standardised by
UV quantitation, 89–102 at
20 nmol/L
NR/(3.0) 5.3% at 26 nmol/L,
8.2% at 20 nmol/L
Immuno Diagnostic
Systems Ltd.
S/P 25 μl, 2-step
procedure w/o
extraction
ELISA, immobilized anti-25OHD,
sheep polyclonal Ab, 25OHD-
labeled with biotin HRP/TMB
Equivalence:
75%/Z100%,
cross-reactivity
NR/Z100%
Calibrators standardised by
UV quantitation, 97–105
NR/(5.0) 5.3% at 39 nmol/L,
4.6% at 40 nmol/L
Immuno Diagnostic
Systems Ltd.
S 10 μl, 2-step
procedure,
Denaturation
DBPþNaOH
CLIA, acridinium-labeled anti-
25OHD, sheep polyclonal Ab
Equivalence: Yes,
cross-reactivity:
1%/NR
Calibrators standardised to
ID-LC-/MS/MS) 25OHD RMP;
traceable to the NIST SRM
2972, recovery not reported
17.5/(6.0) 6.2% at 30 nmol/L,
11.6% at 30 nmol/L
DiaSorin, Liaison,
Total DiaSorin
CLIA, HRP – isoluminol derivative Equivalence: Yes,
cross-reactivity:
1.3%/NR
Calibrators traceable to UV
spectrophotometric analysis
10.0/(NR) 3.8% at 20 nmol/L,
12.2% at nmol/L
Advia, Centaur,
Siemens
S/P 20 μl,
buffered
releasing agent
CLIA, acridinium-labeled mouse
mAb, ﬂuorescein vitamin D
analog, anti-ﬂuorescein mAb,
PMP 1-anilinonaphthalene-8-
sulfonic
Equivalence: Yes
104%/100%, cross-
reactivity: 1.1%/
NR
Calibrators standardised to
ID-LC-/MS/MS, 25OHD RMP;
traceable to the NIST SRM
2972, recovery not reported
10.5(8.0) 4.7% at 34 nmol/L,
11.9% at 34 nmol/L
Architect 1, Abbott S/P 60 μl, 2 step
procedure,
EtOH/
triethanolamine/
ANSA
CLIA, Sheep polyclonal Ab-anti-
25OHD, acridinium-labeled
biotinylated anti-biotin IgG
complex
Equivalence: 82%/
100%, cross-
reactivity: 2.7%/
112%
NR, no mention of
traceability, recovery not
reported
20 (7.8) 3.1% at 58 nmol/L,
4.0% at 58 nmol/L
Roche Elecsys, Roche
Diagnostics
S/P 15 μl, 2 step
procedure,
Dithiothreitol
pH 5.5, then
NaOH
ECL, CBPA, Ruthenium Equivalence: 92%/
100%, cross-
reactivity: 91%/
149%
Standardized against in house
LC-MS/MS standardized to
the NIST standard, recovery
not reported
10 (7.5) 7.8% at 17 nmol/L
Vitros 5600, Vitros S 60 μl, 1 step
procedure, acid
pH
CLIA, Sheep mcAB-anti-25OHD,
Horseradish peroxidase – Luminol
Equivalence: Yes,
cross-reactivity:
Yes 37.4%/34.3%
In house reference
calibrators, Correlation to LC/
MS/MS, recovery not reported
32 (21.6) 7.4% at 56nmol/L,
14.0% at 56 nmol/L
Beckman Dxi,
Beckman–Coulter
S/P 30 μl, 1 step
procedure, Tris
buffered saline
CLIA, Sheep mcAB-anti-25OHD
25OHD, analog AP-conjugate,
Lumi-Phos* 530
Equivalence: Yes,
cross-reactivity:
65%/0%
Calibrators standardised to
ID-LC-/MS/MS, 25OHD RMP;
traceable to the NIST SRM
2972, recovery not reported
11 (3.7) 4.6% at 39 nmol/L,
8.1% at 39 nmol/L
Unless otherwise speciﬁed, the characteristics of the commercial assays are derived from the information given in the respective inserts. Recovery refers to the % of the
exogenously added 25OHD3 (nmol/L) before extraction recovered at completion of the assay. RIA: radio immnuno assay; EIA: enzyme-linked immuno assay; CLIA: chemi
luminescent immuno assay, CBPA: competitive binding-protein assay; ELISA: enzyme-linked immuno sorbent assay; CLIA: chemi luminesent immuno assay; ECL: electro
chemiluminescence S: serum; P: plasma; LOQ: lower limit of quantiﬁcation deﬁned as a measure with a CVo20%; LOD: lower limit of detection deﬁned as the lowest
concentration that can be deﬁned with a conﬁdence of 95%; NR: not reported; CV: coefﬁcient of variation at the lowest concentration tested. EtOH: Ethanol; 3H-25OHD2:
[23,24(n)-3H]-25-hydroxyvitamin D3 or [26(27)-methyl-3H]-25-hydroxyvitamin D3; 125I-CC: vitamin D-23,24,25,26,27-pentanor-C(22)-carboxylic-amide-3-aminopropyl;
ANSA: 8-anilino-1-naphthalene sulfonic acid; IgG: immunoglobulin G; mcAB: monoclonal antibody; BSA: bovine serum albumin; AP: alkaline phosphatase; Lumi-Phos* 530:
trademark of Lumigen Inc. (Southﬁeld, MI); ID-LC-/MS/MS: isotope dilution-liquid chromatography/tandem mass spectrometry; RMP: reference method procedure; NIST:
National Institute of Standards and Technology; SRM: standard reference material
a Personal communication (E Cavalier).
C. Le Goff et al. / Practical Laboratory Medicine 2 (2015) 1–14 5
open B-ring cis-triene structure common to both vitamins D2 and D3 as the hapten, thus ensuring that the antibodies would only
recognize this structure. It should be noted that neither assay kits are standardised with reference material, thereby diminishing their
accuracy. In both cases the lower limit of detection (LoD) is in the range of 3 nmol/L, although, to our knowledge, there are no independent
data to support this claim. DiaSorin and IDS claimed 100% 25OHD recovery from spiked samples. However, for exogenous 25OHD3 and
25OHD2 respectively a 2005 DEQAS survey reported a mean recovery of 82% and 83% for the DiaSorin assay, and 45% and 25% for the IDS
RIA kit [34]. Both methods used an acetonitrile extraction of vitamin D metabolites. Addition of NaOH in the initial denaturation-
extraction procedure of the IDS RIA has been suggested as the source of the difference. This hypothesis can however be dismissed as both
the DiaSorin and IDS assays gave similar results for the specimen containing only endogenous vitamin D. The discrepancy can be
explained, at least in part, by the lower afﬁnity of the IDS primary antibody for 25OHD2 [51]. On the other hand, Glendenning et al. [52]
have reported that the DiaSorin RIA overestimates total 25OHD within the range of 40–60 nmol/L when compared to a HPLC method. The
assays also differ in their imprecision, DiaSorin reporting an intra-assay CV of 11.7% at 21.5 nmol/L and IDS of 5.3% at 26 nmol/L.
6. Automated immunoassays
RIAs gradually gave way to automated enzyme-linked immunoassays (ELISAs), CLIAs or CBPAs. Characteristics of the direct automated
methods found in the manufacturers' information inserts are summarized in Table 1b. As can been appreciated, according to the
manufacturers' respective inserts, 5 out of 6 automated CLIA-based methods measured 25OHD2 and 25OHD3 equivalently (IDS, DiaSorin,
Advia Centaur, Vitros, Beckman) whereas the IDS ELISA assay underestimated 25OHD2 by 25%, the Abbott CLIA by 18% and Roche ECL by
8%. However in the case of the Advia Centaur, Le Goff et al. [53] using native clinical samples reported a 30% mean overestimation (4–59%)
for 25OHD2. These assays exhibited, when reported, variable cross-reactivity for 24,25(OH)2D3 (0% for Beckman to 149% for Roche) and C3-
epi-25OHD3 (1% for the IDS CLIA to 91% for the Roche CBPA). Interestingly, van den Ouweland et al. [54] demonstrated recently, that when
present endogenously, C3-epi-25OHD3 is not recognized in the Roche CPB assay and urge for caution in interpreting recovery data.
It is interesting to note that 4 out of 8 automated assays were directly or indirectly standardized against a NIST Standard Reference
Material (SRM), however none provide information on recovery of exogenous 25OHD3 or 25OHD2. Automated immunoassays, as well as
CBPAs, are based on delicate non-denaturing conditions to free 25OHD from DBP and other serum binding components to allow its
binding either to the kit antibodies or DBP. This step, sensitive to matrix effects, may yield varying results [55,56].
The performance of different commercial assays has recently been reported in independent investigations. Su et al. [57] have reported
that, compared to a Liquid Chromatography Tandem Mass spectrometry method (LC/MS–MS), a CBPA (Diazyme, Poway, CA) exhibited a
positive bias when samples contained only 25OHD3 and negative biases as the 25OHD2/25OHD3 ratios increased (10.8%, 23.6%, 38.4%).
As the DBP in all likelihood recognizes the 25OHD isomers equally, the bias could be explained by the inefﬁcient recovery of 25OHD2.
Holmes et al. [58], compared total 25OHD results in 163 clinical specimens obtained by 3 direct immunoassays, (DiaSorin Liaison assay,
Siemens Centaur, Abbott Architect), to those obtained after extraction and followed by LC/MS–MS and RIA. Their data revealed high
degrees of random variability and bias relative to LC/MS–MS and RIA results. Importantly, the magnitude of the biases and random errors
exceeded the criterion for the total allowable error of a 25OHD test [11] in almost ½ of the clinical specimens and led to misclassify an
appreciable number of study patients as vitamin D deﬁcient. Cavalier et al. [59] also reported a concordance between methods varying
between 65% and 82% when comparing 6 automated platforms to the NIST/NIH VDSP-accredited LC/MS–MS method. As Sempos et al. [10]
have emphasized, this inter-assay variability could lead to misleading conclusions in epidemiological studies aiming at evaluating the
vitamin D status and to limiting the comparability between national surveys. All assays have satisfactory precision, although deﬁned at
variable concentrations.
7. High performance liquid chromatography
Table 2 lists the different HPLC methods published the past 35 years. Eisman et al. [60] published the 1st HPLC method for the
measurement of 25OHD in 1978, followed within a year by Gilbertson et al. [61] and Jones [62]. Variants of these initial methods have been
published until very recently [63–76]. As can be appreciated, although the HPLC-based methods were able to separate 25OHD2 from
25OHD3, the authors used either a single in-house or commercially available labeled 25OHD3 as internal standard or even surrogate
molecules (retinyl acetate, docecanophenone, derivatised 25-hydroxydehydrocholesterol, 1α-OHD) to monitor the recovery of 25OHD,
although reporting in most case concentrations for both isomers. However, as mentioned earlier Stryd et al. [49], questioned in 1978 the
accepted notion that 25OHD2 and 25OHD3 behaved identically during the extraction and chromatographic procedures, and therefore held
that using the recovery of the tracer 3H-25OHD3 to calculate the concentration of the 2 isomers was an error. This led them to report
values only for 25OHD3 contrary to others. This premise can be extended to the proxy tracers. Among variants reported, Shimada et al. [67]
used 2 internal standards: 25OHD2 (IS1) and derivatized 25-hydroxy-7-dehydrocholesterol (IS2) to assess 25OHD3 recovery. However the
methodology used requires clariﬁcation. To start with, they added the 1st internal standard after precipitation of plasma proteins with
ethanol, thereby removing an important step that could lead to misinterpretation. They also performed experiments to evaluate the
“absolute” recovery of 25OHD3. For this part, they added 25OHD3 standards to 7% buffered bovine serum albumin together with the IS1
and performed the extraction. They then added the IS2 after the HPLC process they calculated the peak-height ratios between the 25OHD3,
the IS1 and IS2. It is difﬁcult to conceive how this maneuver allowed the accurate assessment of the endogenous 25OHD. The recovery
studies vary in their structure (labeled or not-labeled tracer, 25OHD or surrogate molecules). Hence it is difﬁcult to assess accurately the
performance of the methods. The accuracy of the methods described is ill-deﬁned, as in most cases no calibrator traceable to a standard
reference material was available. However Hymøller et al. [75] have shown that their method yielded results within acceptable
boundaries, in terms of accuracy and precision, for 25OHD2 and 25OHD3 using the NIST standard reference material 972.
Some investigators have proposed a coulometric electrochemical detection system [68,76] based on the oxidation potential of the
conjugated-diene structure of vitamin D metabolites to quantitate 25OHD after the HPLC step. Although this detection method is as
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Table 2
Physical separation and detection methods.
Reference Sample volume, extraction procedure,
chromatographic procedure, detection
wavelength
Internal standards,
analyte measured
Recovery LOQ (nmol/L) Precision, Intra-assay CV,
Intra-assay CV
Eisman et al. [60] Plasma 4 ml, extraction: MeOH:CHCl3 (50:50
v/v), pre-treatment: Sephadex LH-20,
SkellySolve B: CHCl3 (50:50 v/v), SkellySolve
B: CHCl3:MeOH (18:2:1 v/v), HPLC: porasil
silicic acid column, 2-propanol:hexane
(2.5:97.5 v/v), detection: 254 nm
In-house IS [26,27], 3H-
25OHD3, [3α]3H-
25OHD2, 25OHD2,
25OHD3
3H-25OHD3: 72.2710% NR NR
Gilbertson et al. [61] Serum 1 ml, extraction: CHCl2:MeOH (2:1 v/
v), pre-treatment: silicic acid CH2Cl2:EtOH
(98:2 v/v) then n-hexane, HPLC: porasil silicic
acid column, EtOH:hexane (5:95 v/v),
detector: 254 nm
Commercial IS [24,25],
3H-25OHD3, 25OHD3
3H-25OHD3:
60.8714.4%
NR 25OHD3, 5.2% at 28 nmol/L,
5.5% at 28 nmol/L
Jones [62] Plasma or serum 2 ml, extraction: MeOH:
CHCl3 (2:1v/v), 2-propanol:hexane (4.5:95.5 v/
v), HPLC: Zorbax-SIL MeOH:H2O (98.5:1.5 v/v)
followed by MeOH:H2O (91.0:9.0 v/v), Zorbax-
ODS MeOH:H2O (98.5:1.5 v/v), detection:
254 nm
Commercial IS [26,27],
3H-25OHD3, In-house
IS, [3α]3H-25OHD2,
25OHD2, 25OHD3
3H-25OHD3:
68.876.5%
NR 25OHD3, 9.0% at 30 nmol/L,
16% at 30 nmol/L
Babek et al. [63] Plasma 0.5–3.0 ml, pre-treatment: SPE: Sep-
pak C18 MeOH:H2O (69:31 then 80:20 v/v),
silicic acid HPLC n-hexane-propane-2-ol
(100:2.4 v/v), detection: 254 nm
Commercial IS [23,24],
3H-25OHD3, 25OHD3,
25OHD2
3H-25OHD3: 93% NR 25OHD3: 5%, 25OHD2: 5%,
concentrations not
mentioned
Turnbull et al. [64] Plasma 2.0–3.0 ml, extraction: MeCN pre-
treatment: SPE: Sep-pak C18 MeOH:H2O
(70:30 v/v) then MeCN, derivatisation to
isotachysterols Zorbax-Sil n-hexane-propane-
2-ol (95:5 v/v), detection: 301 nm
Commercial IS [23,24],
3H-25OHD3, 25OHD3,
25OHD2
3H-25OHD3:
54.972.5%
NR 25OHD3: 5.9% at 57 nmol/L,
25OHD2: 6.8% at 14 nmol/L,
25OHD3: 8.0% at 62 nmol/L,
25OHD2: 7.1% at 16 nmol/L
Loo et al. [65] Plasma 1.0 ml PP: MeOH, extraction: n-hexane
1st HPLC: Li-Chrosorb-Si n-hexane-EtOH
(90:10 v/v), 2nd HPLC: Ultraspher-Octyl C-8
MeCN:H2O (80:20 v/v), detection 254 nm
Commercial IS, [26,27],
3H-25OHD3, 25OHD3,
25OHD2
3H-25OHD3:
74.773.4%
NR NR
Norris et al. [66] Plasma/serum 2.0 ml PP: MeOH, pre-
treatment: SPE: Sep-pak C18 (MeOH), 1st
HPLC: Li-Chrosorb-Si n-hexane-propane-2-ol
(91:9 v/v), 2nd HPLC: Spherisorb-ODS MeOH:
H2O (88:12 v/v), detection 285 nm
Commercial IS [23,24],
3H-25OHD3, 25OHD3,
25OHD2
3H-25OHD3:
54.972.5%
25OHD3: 7.5,
25OHD2: 7.5
25OHD3: 7.3% at 28 nmol/L,
25OHD2: 6.4% at 16 nmol/L
Shimada et al. [67] 500 μl Plasma PP: EtOH, extraction: EtOH/KOH
followed by Et2O, pre-treatment: silicic acid
column n-hexane-propane-2-ol (98.5:1.5 v/v)
n-hexane-propane-2-ol (84:16 v/v) HPLC:
J’sphere ODS-HS0, MeCN:H2O (70:30 v/v),
detection 265 nm
In-house IS, 25OHD2,
MBPTD-25OHdC,
25OHD3
25OHD2 55.273.3%,
25OHD3: 59.374.2%
12.5 4.0% at 43.6 nmol/L (average
of 4 determinations), 8.2% at
65.0 nmol/L (average of
4 determinations)
Masuda et al. [68] 100 μl, plasma, extraction MeCl2/MeOH HPLC:
nucleosil 5-C18 column MeCN:MeOH (95:5 v/
v)/HClO4, detection: ECD at þ0.60 V
IS: NR, 25OHD3 25OHD3: 81.575.8%, NR 5.3% at 76 nmol/L, 9.7% at
76 nmol/L
Alvarez et al. [69] 500 μl Plasma PP: EtOH, extraction: n-Hexane/
MeCl2, HPLC: Lichrospher 100 RP-18 MeCN:
MeOH:H2O (90:4:6 v/v), gradient to MeCN:
MeOH (40:60 v/v), detection 267 nm
Commercial IS, 1α-
OHD3, 25OHD2,
25OHD3
1α-OHD3 93.077.9%,
25OHD2: 81.574.7%,
25OHD3: 88.075.1%
25OHD2: 12.5,
25OHD3: 12.5
25OHD2: 6.1% at 15 nmol/L,
25OHD3: 7.7% at 22.5 nmol/
L, 25OHD2: 10.8% at 15 nmol/
L, 25OHD3: 11.8% at
22.5 nmol/L
Brunetto et al. [70] 1 ml Plasma, extraction: EtOH:MeCN HPLC:
Spherisorb C18, gradient: MeCN:phosphate
buffer pH6.5 (20:80 v/v) to MeOH:MeCN:THF
(65:20:15 v/v), detection: 265 nm
No IS, 25OHD3 Spiked sample,
25OHD3: 91% at
20 nmol
25OHD3: 7.5 25OHD3: 2% at 17.5 nmol/L,
25OHD3: 2% at 17.5 nmol/L
Quesada et al. [71] 1 ml Serum PP: EtOH, extraction: n-hexane:
MeCl2 HPLC: Ultrabase C18 column, gradient
from MeOH:H20 (90:10 v/v) to MeOH:
propane-2-ol (90:10 v/v), detection: 265 nm
Commercial IS, retinyl
acetate, 25OHD3
NR 25OHD3: 0.75 25OHD3: 4.3%,
concentration: NR 25OHD3:
9.2%, concentration: NR
Lensmeyer et al. [72] Serum 1 ml PP (MeCN), extraction: HPLC: SB-
CN column, MeOH:H2O (67:33 v/v), detection:
275 nm
Commercial IS,
laurophenone
(dodecanophenone)
25OHD3, 25OHD2
Exogenous 25OHD2:
101.279.4% (8–
253 nmol/L), 25OHD3:
95.177.6% (11–
260 nmol/L)
25OHD2: 12.5,
25OHD3: 12.5
25OHD2: 13% at 11.0 nmol/L,
25OHD3: 8.5% at 28.9 nmol/L
Granado-Lorencio
et al. [73]
1 ml Serum PP: EtOH, extraction: n-hexane:
MeCl2 HPLC: Spheri-5-ODS column, gradient
from MeCN:MeOH (85:15 v/v) to MeCN:
MeCl2:MeOH (70:20:10 v/v/v), detection:
267 nm
Commercial IS, retinyl
acetate 25OHD (no
distinction between
25OHD3 and 25OHD2)
25OHD: 485% (no
details given)
NR o10% concentration: NR,
o10% concentration: NR
Kand’ár et al. [74] 500 μl Plasma PP: EtOH, extraction: SPE
Discovery DSC-18 MeOH:H2O (2:3 v/v), MeOH.
HPLC: Purospher STAR-RP-18e MeOH/H2O
(95:5 v/v), detection: 265 nm
Commercial IS, retinyl
acetate 25OHD3
Spiked samples,
25OHD3: 96.977.6%
from 5 to 100 nm/L
10 nmol/L
(2.5 nmol/L)
25OHD3: 5.3% at 57 nmol/L,
25OHD3: 8.7% at 67 nmol/L
Hymøller et al. [75] 1.5 ml Plasma saponiﬁcation: MeOH/KOH/ASC,
extraction: heptane HPLC: YMC-C30 RP
25OHD2:0.2% at 150 nmol/L,
25OHD3: 0.6% at 150 nmol/L
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efﬁcient as methods based on UV, it is not widely adopted by clinical laboratories. This may be due to the demanding maintenance of the
detectors.
8. Mass spectrometry
Watson et al. [77] were among the ﬁrst to describe a LC/MS–MS method for the measurement of vitamin D2, vitamin D3, and their
respective mono- and di-hydroxylated metabolites. The clinical use of LC/MS–MS has since steadily grown, especially for the quantitation
of lowmolecular weight analytes such as vitamins, hormones and steroids. According to the October 2013 DEQAS (www.deqas.org), 25% of
the participants reported using this technology. Vogeser [78] and van den Ouweland et al. [79] have published extensive reviews on the
subject. Table 3 highlights, in a chronological order, the methodology and performance characteristics of methods published during the
last 15 years [80–103]. Methods that include derivatization of the vitamin D metabolites with Cookson-like reagents are worth
mentioning. Although sensitive and speciﬁc, they are not transposable for routine analysis in clinical laboratories but should be considered
in clinical studies for vitamin D metabolite proﬁling [80,81,89,103]. The advantages of the addition of a nitrophenyl group to the
conjugated-diene portion of the secosteroids are two-fold. It increases the ionization efﬁciency and the analytical sensitivity by moving
molecular masses of the parent ions to a regionwhere there is reduced background noise thereby increasing the signal/noise ratio. The LC/
MS–MS methods cited in Table 3 have all quantitation limits below 10 nmol/L well below the concentration considered as severe
hypovitaminosis (25 nmol/L) [83–88,90,93–102].
Three candidate reference methods have been proposed in the last 10 years. In 2004, Vogeser et al. [82] published the 1st candidate
reference method for the measurement of 25OHD3 by stable isotope-dilution LC/MS–MS applicable to clinical laboratory practice. Their
method involved a protein denaturation process to release the bound vitamin D metabolites, and on-line solid-phase extraction before the
reverse-phase HPLC coupled to the MS–MS with the detector set in the electrospray atmospheric pressure ionization in the positive mode.
In 2010 and 2011, Tai et al. [91] and Stepman et al. [92] proposed each a candidate method that differed from that of Voseger et al. [82] and
from each other in a number of ways. Whereas Vogeser et al. [82] utilized a 25OHD3 internal standard containing 3 Deuterium atoms and
1 13C atom, Tai et al. [91] used tri-deuterated 25OHD3 and 25OHD2, and Stepman et al. [92] hexa-deuterated hydroxylated vitamins D2 and
D3. Differences lied also in the sample volume (200 μl to 2 ml), sample preparation (liquid–liquid or solid-phase extraction), HPLC
conditions and detection process [APCIþ or ESIþ and multiple reaction monitoring (MRM) or single ion monitoring (SIM)]. Despite their
differences, the IFCC Joint Committee for Traceability in Laboratory Medicine (JCTLM) recognized Tai et al.'s [90] and Stepmans et al.'s [92]
as reference method procedures (RMP). Furthermore, the NIST has used Tai et al.'s [91] candidate RMP to certify the concentrations of 25
(OH)D3 and 25(OH)D2 in their Standard Reference Material for Vitamin D in human serum to validate the accuracy for the methods used in
clinical laboratories.
9. Problems related to LC/MS–MS
Undoubtedly, LC/MS–MS methods offer many advantages. First they have the potential of measuring simultaneously all species of the
25-hydroxylated vitamin D as well as downstream dihydroxylated metabolites. Second, they are not bound to conditions imposed by the
manufacturers, although commercial “turn-key” tandem-mass spectrometry methods are now available. Gervasoni et al. [104] have
recently reported a comparison between 2 such methods suitable for application in clinical laboratories. Third, the technological progress
has allowed LC/MS–MS, using Single Ion Monitoring (SIM), to reach high analytical speciﬁcity and sensitivity while resorting to relatively
short chromatography run time, essential when considering a clinical application.
The development of advanced informatics coupled to the simpliﬁed use of LC/MS–MS equipment have led users to underestimate the
complexity of the analytical processes involved in the quantitation of vitamin D metabolites and hence to undervalue limitations that may
compromise the dependability of the data. Indeed, LC/MS–MS is not devoid of hindrance when considering clinical laboratories. Firstly, the
instruments are costly, and their complexity requires well-trained personnel for their operation and maintenance. Secondly, matrix effects
may be a signiﬁcant drawback when Electrospray (ESI) or Atmospheric Pressure Chemical Ionization (APCI) sources are employed. Hence,
better sample clean-up and lengthier chromatography are required. Thirdly, high sensitivity and high speciﬁcity may be mutually
Table 2 (continued )
Reference Sample volume, extraction procedure,
chromatographic procedure, detection
wavelength
Internal standards,
analyte measured
Recovery LOQ (nmol/L) Precision, Intra-assay CV,
Intra-assay CV
column, gradient: H2O:EtOH (95:5 v/v), H2O:
EtOH (60:40 v/v); H2O:EtOH (10:90 v/v),
detection: 265 nm
Commercial IS,
1αOHD3, 25OHD2,
25OHD3
25OHD2: 101.0% at
75 nmol/L, 25OHD3:
100.3% at 75 nmol/L
1.3 nmol/L
(Metabolite not
speciﬁed)
Nurmi et al. [76] 500 μl Serum PP: MeOH:propane-2-ol (80:20
v/v), extraction: n-hexane HPLC: Supelco
Discovery HS F5, gradient: 60 mM NaClO4/
HClO4/MeOH/MeCN (30:50:20 v/v/v), NaClO4/
HClO4/MeCN, (10:90 v/v), detection: CEAD
630 mV
No IS, 25OHD2,
25OHD3
25OHD2: 72% at
24 nmol/L, 25OHD3:
61% at 24 nmol/L
25OHD2: 12,
25OHD3: 12
25OHD3: 6.2% at 27.5 nmol/L
PP: protein precipitation; SPE: solid phase extraction; LLE: liquid–liquid extraction; OLTFE: on line turboﬂow extraction; ECD: electrochemical detection; CEAD: coulometric
electrode array detector. 25OHdC: 25-Hydroxy-7-dehydrocholesterol; 1α-OHD3: 1-alpha-hydroxyvitamin D3; MBPTD: 4-[4-(6-methoxy-2-benzoxazolyl)phenyl]-1,2,4-
triazoline-3,5-dione; MeNH2: methyl amine; MeOH: methanol; EtOH: ethanol; NH4Ac: ammonium acetate; MeCN: acetonitrile: Et2O: diethyl-ether; KOH: potassium
hydroxide; MeCl2: dichloromethane; HClO4: perchloric acid; THF: tetrahydrofuran; ASC: 20% ascorbic acid water solution; IS: internal standard; NR: not reported.
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Table 3
Mass spectrometric methods applicable to clinical laboratories.
Ref Sample volume, extraction
procedure, chromatographic
procedure, ionization, mode of
monitoring
Internal standards, analyte
measured, acquisition settings, m/z
Recoverya LOQ nmol/L,
LOD nmol/L
Precision (CV) Intra-assay Inter-
assay
Higashi et al. [80] Plasma 20 μl, PP: MeCN, extraction:
LLE (AcOEt), derivatisation (DMEQ-
TAD) HPLC: J'sphere ODS H-80
MeCN/H2O (3/2 v/v) TMS: APCIþ
SIM
In-house IS: 25OHD4: 760.1,
25OHD3: 746.1, 25OHD2: 758.1
25OHD3: 98.8–
109.8%
(12.5 nmol/L),
25OHD2: 101.1–
104.2%
(12.5 nmol/L)
25OHD3: 7.5,
25OHD2: 7.5,
25OHD3: 1.3
25OHD3: 3.24% at 21.9 nmol/L,
25OHD2: 3.17% at 12.5 nmol/L
Higashi et al. [81] Plasma 20 μl, PP: MeCN, extraction:
LLE (AcOEt), derivatisation (NPTAD)
HPLC: J'sphere ODS H-80 MeOH/
H2O (7/1 v/v) TMS: APCI SIM
In-house IS: 25OHD4: 634.2,
25OHD3: 620.2
Analytical
recovery: NR
25OHD3: 7.5,
25OHD3: 1.3
25OHD3: 8.2% at 7.5 nmol/L
Vogeser et al. [82] Serum 200 μl, NaOH, PP: MeCN,
extraction: on-line SPE: Oasis HLBs
HPLC: LiCrosphers 100 RP-18
MeOH/NH4Ac:0.5mM (90/10 v/v)
TMS: ESIþ
In-house IS: 2H3, 13C1-25OHD3:
4054159, 25OHD3: 4014159
25OHD3:
9171.6% IS
(325 nmol/L),
injected into TMS/
IS,
extractedþTMS
NR 25OHD3: 12% at 14.5 nmol/L
Tsugawa et al. [83] Serum 100 μl, PP: MeOH,
extraction: SPE: Bond-Elute C18s
HPLC: CapCell PAK C-18 UG120s
MeOH/H2O (95/5 v/v) TMS: APCIþ
MRM
In-house IS: 2H6-25OHD3:
4074263, 25OHD3: 4014257,
25OHD2: 4134255
25OHD3: 103.8%
(50 nmol/L),
25OHD2: 98.8%
(7.5 nmol/L)
25OHD3: 2.5,
25OHD2: 2.5
25OHD3: 5.7% at 50 nmol/L,
25OHD2: 4.5% at 7.5 nmol/L,
25OHD3: 2.5% at 47.5 nmol/L,
25OHD2: 5.1% at 8.0 nmol/L
Maunsell et al. [84] Serum 100 μl, PP: MeOH:Propanol
(80:20 v/v), Extraction: LLE:
n-Hexane HPLC: BDS C8s
ThermoHypersil
MeOH4H2Oþ0.05% CHO2H
Gradient TMS: ESIþ MRM
In-house IS: 2H6-25OHD3:
407.24389.4, 25OHD3:
401.84383.5, 25OHD2:
413.54395.4
25OHD3: 91–110%
at 128–256 nmol/
L, 25OHD2: 94–
108% at 158–
317 nmol/L
25OHD3: o4.0,
25OHD2: o5.0
25OHD3: 6.2% at 16 nmol/L,
25OHD3: 5.1% at 55 nmol/L,
25OHD2: 9.5% at 52 nmol/L
Chen et al. [85] Serum 200 μl, PP: MeCN Extraction:
SPE: Oasis HLBs MeOH/H2O (30/70
v/v); MeCN/MeOH (50/50 v/v),
HPLC: SupelCosilsLC-18-DB EtOH:
H2O (83:17 v/v) TMS: APCIþ MRM
Commercial IS: 2H6-25OHD3:
407.74389.7, 25OHD3:
401.44383.4, 25OHD2:
413.44395.4
25OHD3: 9972%
at 34.2–
132.8 nmol/L,
25OHD2:
9570.8% at 32.2–
115.5 nmol/L
25OHD3: 4.0,
25OHD2: 15.5,
25OHD3: 1.2,
25OHD2: 4.6
25OHD3: 6.2% at 34 nmol/L,
25OHD2: 8.7% at 23 nmol/L,
25OHD3: 11% at 34 nmol/L,
25OHD2: 16% at 23 nmol/L
Bunch et al. [86] Serum 100 μl, PP: MeOH Extraction:
OLTFE HPLC: Hypersil Gold aQs
MeOH/H2O (95/5 v/v) TMS: APCIþ
MRM
In-house IS 2H6-25OHD3:
407.24389.4, 25OHD2:
413.54395.4, 25OHD3:
401.84383.5
25OHD3: 3.0,
25OHD2: 4.6
Hojskov et al. [87] Serum 100 μl, PP: MeCN,
extraction: automated LLE: 96-well
Isolute HM-N plates/diatomaceous
earth; Heptane HPLC: Synergi
MAX-RPs MeOH/2.0 mM NH4Ac
(85/15 v/v) TMS: APCIþ MRM
Commercial IS 2H6-25OHD3:
407.44371.4 25OHD3:
401.44365.2, 25OHD2:
413.44395.4
NR 25OHD3: o10,
25OHD2: o10
25OHD3: 9.4% at 32 nmol/L,
25OHD2: 8.6% at23.4 nmol/L
Hermann et al. [88] Serum 100 μl, PP: MeCN HPLC:
Supelcosil LC-8s
H2O4MeOH4H2O/MeOH (98/2 v/
v)4Toluene APPIþ MRM
Commercial IS 2H6-25OHD3:
3894371, 2H6-25OHD2 4014383,
25OHD3: 3954377, 25OHD2:
413.54395.4
108–113%,
expressed as total
25OHD added
(45–90 nmol/L)
25OHD3: 1.3,
25OHD2: 1.3
25OHD: 5.7% at 17 nmol/L,
25OHD: 8.7% at 17 nmol/L
Ding et al. [89] Serum 200 μl, PP: MeCN,
extraction: SPE Oasis HLBs MeCN;
EtOAc Derivatisation (PTAD)/MeCN
HPLC: ACQUITY BEH C18s 0.1%
CHO2H/H2O/MeNH2; CHO2H/MeOH
gradient TMS: ESIþ MRM
Commercial IS 2H6-25OHD3:
6134298, 2H6-25OHD2 6254298,
25OHD3: 6074298, 25OHD2:
6194298
2H6-25OHD3:
84.972.4%b, 2H6-
25OHD2:
79.3714.4%b
#25OHD3:
0.025,
#25OHD2:
0.025
#25OHD3: 3.8% at 0.025 nmol/L,
#25OHD2: 1.6% at 0.025 nmol/L
Van den Ouweland
et al. [90]
Serum 250 μl, PP: NaOH-MeCN/
MeOH (9/1 v/v) SPE: Strata C18-Es
H2O-MeOH/H2O (60/40 v/v)-MeOH
HPLC: ACQUITY UPLC BEH C18s
0.1% CHO2H/2 mM NH4Ac; MeOH/
CHO2H (99.7:0.3 v/v) gradient,
TMS: AP-ESIþ SRM
Commercial IS 2H6-25OHD3:
407.54159.2, 25OHD3:
401.54159.2, 25OHD2:
413.4483.1
25OHD3: 94.9–
106.9% at 49.9–
99.9 nmol/L,
25OHD2: 82.7–
100.3% at 54.3–
108.6 nmol/L
25OHD3: 3.5,
25OHD2: 2.0,
25OHD3: 1.5,
25OHD2: 1.2
25OHD3: 2.7% at 64.9 nmol/L,
25OHD2: 4.2% at 33.3 nmol/L,
25OHD3: 6.0% at 64.9 nmol/L,
25OHD2: 3.8% at 33.3 nmol/L
Tai et al. [91] Serum 2 g pH adjusted to 9.8
(Na2CO3) LLE, extraction: n-hexane/
EtAc (50/50 v/v), Residue dissolved
in MeOH HPLC: Zorbax CB-CN
column H2O/MeOH (34/66 v/v)
TMS: APCIþ MRM
Commercial IS 2H3-25OHD3
4044386 2H3-25OHD2 4164398,
25OHD3 C3-epi-25OHD3:
4014383, 25OHD2 C3-epi-
25OHD2: 4134395, Stds traceable
to NIST
25OHD3: 100.0–
10%, 25OHD2:
98.0–100.1%
25OHD3:
0.15 ng/g,
25OHD2: 0.1 ng/
g
25OHD3: 0.4% at 6.31 ng/g,
25OHD2: 0.9% 0.86 ng/g,
25OHD3: 0.6% at 6.31 ng/g,
25OHD2: 0.86% 0.86 ng/g
Stepman et al. [92] Serum 250 μl, extraction: LLE:
NaOH/n-hexane Sephadex LH-20
chromatography MeOH/CHCl3/
cC6H14 (1/4/8, v/v/v)
2-dimensional UPLC
Chromatography 1:Acquity BEH
Commercial IS 2H6-25OHD3
407.34159.3, 2H6-25OHD2
419.44159.4, 25OHD3:
401.34159.3, 25OHD2:
413.44159.4C3-epi-25OHD3
25OHD3: 71%
74%c, 25OHD2:
70%78%c
25OHD3:
1.1270.05,
25OHD2:
1.2270.05
25OHD3: 1.4% at 30.8 nmol/L,
25OHD2: 2.0% at 64.1 nmol/L,
25OHD3: 1.7% at 30.8 nmol/L,
25OHD2: 1.1% at 64.1 nmol/L
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Table 3 (continued )
Ref Sample volume, extraction
procedure, chromatographic
procedure, ionization, mode of
monitoring
Internal standards, analyte
measured, acquisition settings, m/z
Recoverya LOQ nmol/L,
LOD nmol/L
Precision (CV) Intra-assay Inter-
assay
300C4s, column 2: Acquity BEH
C18s column-25OHD2 2: Zorbax
SB-CNs column-25OHD3, step
gradients MeOH/H2O/CHO2H (50/
50/0.025) MeOH/H2O/CHO2H (95/
5/0.025) TMS: ESIþ SIM
401.34159.3, Stds Traceable to
NIST
Adamec et al. [93] Serum 100 μl, extraction: LLE:
Acetone HPLC: ACE3C8s column,
gradient: H2O/MeOHþ1% toluene
TMS: APPIþ MRM
Commercial IS 2H6-25OHD3
407.34263.3, 2H6-25OHD2
419.34401.2, 25OHD3:
401.24257.2, 25OHD2:
413.34337.2, Stds traceable to NIST
25OHD3: NR,
25OHD2: NR
25OHD3: 2.0,
25OHD2: 2.0
25OHD3: 3.7% at 5 nmol/L,
25OHD2: 16.7% at 5.0 nmol/L,
25OHD3: 15.4% at 5.0 nmol/L,
25OHD2: 14.0% at 5.0 nmol/L
Wang et al. [94] Plasma 1 ml, PP: MeCN LLE: EtOAc,
derivatisation: PTAD HPLC:
Hypersil Golds column MeCN/
H2Oþ0.1% CHO2H gradient (40/60;
60/40; 90/10, 40/60 v/v) TMS: ESIþ
MRM
Commercial IS 2H6-25OHD3
5644298, 25OHD3: 5584298
25OHD3: 73%
72% (BSA matrix)
25OHD3: 0.125,
25OHD3: 0.01
25OHD3: 2.1% at 25 nmol/L,
25OHD3: 7.0% at 25.0 nmol/L
Bogusz et al. [95] Serum 100 μl, PP: MeOH/MeCN/
0.05 M ZnSO4 (6.5/1/2 v/v/v) HPLC:
Kinetex C18 NH4CHO2H/MeOH
Gradient (70/30; 90/10; 70/30)
TMS: APCIþ MRM
Commercial IS 2H6-25OHD3
3894371 3894211, 2H6-25OHD2
4014 383 4014209, 25OHD3:
3834365 3834211, 25OHD2:
3954209 3954269, Stds traceable
to NIST
25OHD3: 98%,
25OHD2: 97%
25OHD3: 3.0,
25OHD2: 1.5,
25OHD3: 1.5,
25OHD2: 0.5
25OHD3: 3% at 41.7 nmol/L,
25OHD2: 4% at 42.1 nmol/L
Baecher et al. [96] Serum 200 μl, PP: MeCN On-line
SPE: LiChrosphers column MeOH/
H2O (5/95 v/v) HPLC: Kinetexs PFP
column MeOH/0.5 mM NH4Ac (75/
25 v/v) TMS: APCIþ MRM
Commercial IS 2H6-25OHD3
407.34263.2, 407.34159.2,
25OHD3: 401.34257.2,
401.34159.2, 25OHD2:
413.44159.2C3-epi25OHD3
401.34257.2, 401.34159.2, NIST
SRM 2972 (levels 1-4) used for
comparison
25OHD3: NR,
25OHD2: NR, C3-
epi25OHD3, 95.5%
at 5.05 nmol/L
25OHD3: 4.0,
25OHD2:
3.9C3-epi25,
OHD3: 2.0
25OHD3: 3.1% at 39.8 nmol/L,
25OHD2: 4.9% at 27.5 nmol/L,
C3-epi25O,HD3: 4.2% at
20.1 nmol/L 25OHD3: 3.8% at
39.8 nmol/L, 25OHD2: 3.4% at
27.5 nmol/L, C3-epi25O, HD3:
3.4% at 20.1 nmol/L
Farrell et al. [97] Serum 150 μl, PP: 2.0 M ZnSO4/
MeOH TMS: 0.2 M/MeOH, SPE:
Oasis μElution HLB plate MeOH/
H2O (60/40 v/v) 2 mM NH4Acþ0.1%
CHO2H/MeOH/2 mM NH4Acþ0.1%
CHO2H (27/73 v/v) UPLC: ACQUITY
BEH C8s 2 mM NH4Acþ0.1%
CHO2H/MeOH/2 mM NH4Acþ0.1%
CHO2H Gradient from (27/73 v/v) to
(98/2 v/v) ESIþ MRM
Commercial IS 2H6-25OHD3
407.34159.1, 2H3-25OHD2
416.34398.3, 25OHD3:
401.34383.5, 401.34159.1,
25OHD2: 413.3483.1,
413.34395.3
25OHD3: NR,
25OHD2: NR
25OHD3: 2.0,
25OHD2: 2.0,
25OHD3: 0.5,
25OHD2: 0.5
25OHD: 1.6% at 79 nmol/L,
25OHD: 2.0% at 79 nmol/L
Lensmeyer et al. [98] Serum 300 μl, PP: MeCN/2 mM
ZnSO4 (87/13 v/v)/MeOH,
extraction: SPE Strata C18Es
MeCN/H2O (45/55 v/v), Acetone/
MeCN (20/80 v/v) HPLC: Zorbax
cyanopropyl column MeOH/H2O
(67/33 v/v), TMS: APCIþ MRM
IS: NR 25OHD3: 383.34211.1,
25OHD2: 395.34209.1C3-epi,
25OHD3 383.34211.1
NR NR NR
Thibault et al. [99] Serum 200 μl, PP: MeCN On-line
SPE: X-Terra C18 MeOH/0.1%
CHO2Hþ2 mM NH4Ac in H2O (98/2
v/v)/0.1% CHO2Hþ2 mM NH4Ac in
H2O (68/32 v/v) HPLC: Sunﬁre C18
MeOH/0.1% CHO2Hþ2 mM NH4Ac
in H2O (98/2 v/v)/ 0.1%
CHO2Hþ2 mM NH4Ac in H2O (85/
15 v/v), TMS: ESIþ MRM
Commercial IS [2H6]25-OHD3
407.54371.3, [2H6]25-OHD2
419.44355.2, 25OHD3:
401.44365.3, 25OHD2:
413.44355.3
25OHD3: 4,
25OHD2: 3
25OHD3: 3.4% at 59.8 nmol/L,
25OHD2: 1.8% at 99.5 nmol/L,
25OHD3: 5.9% at 66.7 nmol/L,
25OHD2: 5.9% at 101.3 nmol/L
Strathmann et al.
[100]
Serum 200 μl extraction: 1 M
NaOH/n-heptane HPLC: XTerra MS
C8þRestek columns, NH4Ac/0.1%
CHO2H in MeOH/H20 (95/5 v/v),
TMS: APCIþ MRM
Commercial IS [2H6]25-OHD3
407.34371.3, [2H6]25-OHD2
419.44355.2, 25OHD3:
401.34355.3, 25OHD2:
413.44355.3, Stds traceable to
NIST
25OHD3: 80–116%
(23.4 nmol/L),
25OHD2: 94–115%
(23.4 nmol/L)
25OHD3: 1.95,
25OHD2: 0.6
25OHD3: 2.9% at 58 nmol/L,
25OHD2: 2.8% at 85 nmol/L,
25OHD3: 9.6% at 63 nmol/L,
25OHD2: 6.2% at 95 nmol/L
Mochizuki et al. [101] Serum or plasma 25 μl, PP: MeCN
2-dimension HPLC: SPE: Turboﬂow
XL C18-Ps column, step gradient
0.1% CHO2H; MeCN/propanol-2ol/
acetone (44/40/20 v/v/v); MeOH/
0.1% CHO2H HPLC: Hypersil Golds
column 0.1% CHO2H; MeOH/0.1%
CHO2H TMS: APCIþ SRM
Commercial IS [2H6]25-OHD3
389.34263.2 25OHD3:
383.34365.2 25OHD2:
395.34377.4 Stds traceable to NIST
25OHD3: 102.6–
106% (36.9–
59.8 nmol/L),
25OHD2: NR
25OHD3: 2.2,
25OHD2: 3.5,
25OHD3: 0.8,
25OHD2:2.2
25OHD3: 5.2% at 18 nmol/L,
25OHD2: 10.6% at 18 nmol/L,
25OHD3: 7.2% at 18 nmol/L,
25OHD2: NR
Zhang et al. [102] Serum 200 μl, PP: MeOH,
extraction: n-heptane HPLC:
Commercial IS [2H3]-25OHD3
404.34368.2, [2H3]-25OHD2
25OHD3: Z62%
(125–200 nmol/
25OHD3: 6.2,
25OHD2: 6.2,
25OHD3: 2.2% at 18 nmol/L,
25OHD2: 2.1% at 18 nmol/L,
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exclusive in the SIM mode when interfering compounds with identical precursor and product ions co-elute with vitamin D metabolites
[78,105,106]. The example of 1α-OHD and 7α-OH-4-cholestene-dione (a marker of bile acid malabsorption) as being potential interfering
substances in the LC/MS–MS analysis, but resolved by a more elaborate HPLC step illustrates this point [84]. The selection of a second or
third product ion that does not interfere also helps solving speciﬁcity-related problems. For example 25OHD2, 25OHD3 and their
respective C3-epimers, present in high concentration in infants’ serum [41,42], may be distinguished using different SIM transitions
although sharing the same product ions [41,87,89,108,109]. Knox et al. [107], recognizing that the puriﬁcation steps are time-consuming in
the perspective of clinical laboratories, proposed a procedure that involves protein precipitation with methanol and a robotized 6-step
solid-phase extraction, that could handle up to 300 samples per day. This procedure should yield cleaner extracts before injection on the
LC/MS–MS instrument, decrease background noise and increase sensitivity.
10. The present and the future
As speciﬁc as LC-TMS may be for the measurement of vitamin D metabolites, accuracy and precision depend on strict standardization
procedures. These aspects were until recently Achilles’ heel of this ﬁeld and discredited the threshold deﬁnition for the vitamin D
nutritional status. The coefﬁcients of variation in a 2013 DEQAS survey, varying between 11 to 25% for all tested laboratory methods (437
participants) and between 9.7% and 11.3% for MS–MS-based methods (147 laboratories), illustrate the inter-laboratory differences. Carter
et al. [110] have reported in a detailed study of analytical performance of the laboratories using LC-TMS, an 11% positive bias with respect
to the RMP and suggested that it was due to the inclusion of the C3-epimer, that most laboratories could not separate from 25OHD3. At
that time, the lack of a RMP and SRM prohibited the evaluation of the accuracy. The recent SRM 972a and calibration solutions developed
by the NIST [111,112] will improve the analytical performance of all methods, as Cavalier et al. [113] have shown for automated methods.
11. Conclusions
The different serum 25OHD values obtained through the years with different methods may have lead to misclassiﬁcation of patients in
terms of the vitamin D nutritional status. The historical thresholds deﬁning vitamin D sufﬁciency, insufﬁciency and deﬁciency, upon which
supplementation decisions are taken, should to be employed with caution. Cavalier et al. [114] have made the point that for assuring the
“optimal” serum 25OHD concentration (75 nmol/L), the measured value could vary from 50 to 100 nmol/L, and that the threshold should
be method-speciﬁc. The C3-epi-25OHD3 present in high concentration in infants' serum and to a lesser extent in adults, remains an issue
as there are diverging opinions on the biological action of C3-epi-1α,25(OH)2D3 [19,20,115,116]. Whatever the answer is, C3-epi-25OHD3
should be quantiﬁed when evaluating the vitamin D nutritional status. The recently developed reference method procedures and certiﬁed
reference and calibration solutions developed by the NIST, to which all laboratories performing 25OHD assays are urged to adhere, will
improve the analytical performance of all methods.
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Table 3 (continued )
Ref Sample volume, extraction
procedure, chromatographic
procedure, ionization, mode of
monitoring
Internal standards, analyte
measured, acquisition settings, m/z
Recoverya LOQ nmol/L,
LOD nmol/L
Precision (CV) Intra-assay Inter-
assay
Zorbax SB-C18, Step Gradient:
2 mM NH4Ac/0.1% CHO2H–H2O;
2 mM NH4Ac/0.1% CHO2H–MeOH,
TMS: ESIþ MRM
416.34358.2, 25OHD3:
401.34365.2, 25OHD2:
413.34355.2
L), 25OHD2:
Z72% (18–
200 nmol/L)
25OHD3: NR,
25OHD2: NR
25OHD3: 4.4% at 18 nmol/L,
25OHD2: 5.0 at 18 nmol/L
Kaufmann et al. [103] Serum 100 μl, PP: 0.1 M HCl/0.2 M
ZnSO4/MeOH, extraction:
n-hexane/t-butyl ether (1/1 v/v),
derivatisation (DMEQ-TAD)/AcOEt
UPLC: BEH-Phenyl column, MeOH/
H2O gradient, TMS: ESIþ MRM
Commercial IS 2H3-25OHD3:
6134298, 2H3-25OHD2 6254298
25OHD3: 746.64468, 25OHD2:
758.64468
25OHD3: NR,
25OHD2: NR
25OHD3: 0.25,
25OHD2: 0.25,
25OHD3: 0.10,
25OHD2: 0.10
25OHD3: 3–4% at 55 nmol/L,
25OHD2: 3–4% at 83 nmol/L,
25OHD3: 4–7% at 55 nmol/L,
25OHD2: 4–7% at 83 nmol/L
HPLC: high performance liquid chromatography; UPLC: UlLC: performance liquid chromatography; MS: mass spectrometry; TMS: tandem-mass spectrometry; AP:
atmospheric pressure; ESI: electron spray ionization; APCI: atmospheric pressure chemical ionization; APPI: atmospheric pressure photo-ionization; ID: isotope dilution;
MRM: multiple reaction monitoring; SRM: selected reaction monitoring; PP: protein precipitation; SPE: solid phase extraction; LLE: liquid/liquid extraction; OLTFE: on-line
turboﬂow extraction; DMEQ-TAD: 4-[2-(6,7-dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalyl)ethyl]-1,2,4-triazoline-3,5-dione; NPTAD: 4-(4-Nitrophenyl)-1,2,4-triazoline-
3,5-dione; PTAD: 4-phenyl-1,2,4-triazoline-3,5-dione; EAD: enzyme-assisted derivatisation; GP: Girard reagent P reagent (1-(carboxymethyl)pyridinium chloride hydrazide);
25OHdC: 25-Hydroxy-7-dehydrocholesterol; 1α–OHD3. 1-alpha-hydroxyvitamin D3 AcOEt: ethyl acetate; MeNH2: methyl amine; MeOH: methanol; EtOH: ethanol; NH4Ac:
ammonium acetate; MeCN: acetonitrile: Et2O: diethyl-ether; KOH: potassium hydroxide; MeCl2: dichloromethane; HClO4: perchloric acid; THF: tetrahydrofuran; ASC: 20%
ascorbic acid water solution; CHO2H: formic acid; IS: internal standard; NR: not reported; NIST: National Institute of Standards and Technology (Gaithersburg, USA); SRM:
standard reference material; levels 1–4: level 1: human serum; level 2: human serum diluted with horse serum to achieve a lower 25(OH)Dx concentration; level 3: human
serum fortiﬁed with 25(OH)D2; and level 4: human serum fortiﬁed with 3-epi-25(OH)D3.
a Recovery: exogenously added vitamin D metabolite.
b % Recovery7SD for the 2 deuterated compounds at a 50 fmol/μl fortiﬁcation level.
c Expressed as % recovery of the NIST-certiﬁed values.
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